# Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Canonical URL: https://biopharmsignal.com/news/ERAS/erasca-announces-closing-of-upsized-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares
Ticker: ERAS
Company: Erasca
Source: Erasca
Published: 2026-01-23 21:01 EST
Original Source URL: https://investors.erasca.com
## Summary

SAN DIEGO , Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously

## Article Body
SAN DIEGO , Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously
## Recent Company News
- 2026-05-27 12:00 EST — [Erasca to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference) — Source: Erasca
- 2026-05-11 20:01 EST — [Erasca Reports First Quarter 2026 Business Updates and Financial Results](https://biopharmsignal.com/news/ERAS/erasca-reports-first-quarter-2026-business-updates-and-financial-results) — Source: Erasca
- 2026-05-11 11:00 EST — [Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)](https://biopharmsignal.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-to-evaluate-eras-0015-in-combination-with-keytrudar-pembrolizumab) — Source: Erasca
- 2026-05-06 12:00 EST — [Erasca to Present at the Bank of America Securities Health Care Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-health-care-conference) — Source: Erasca
- 2026-04-27 20:01 EST — [Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors](https://biopharmsignal.com/news/ERAS/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors) — Source: Erasca
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)